Date: 2013-09-03
Type of information: Grant
Company: Volition Rx (Singapore)
Investors: European Eurostars Programme (EU)
Amount: €779,493
Funding type: grant
Planned used: The project aims to develop new applications of the Nucleosomics biomarker technology in inflammatory disease. The research will build on VolitionRx’s ongoing cancer diagnostic research program. VolitionRx’s contribution to the project is to develop novel NuQ® biomarkers for immune response. VolitionRx will use its proprietary Nucleosomics® platform for biomarker development exploiting UK-based Alcyomics\' proprietary ex-vivo Skimmune™ model. Under the grant, VolitionRx will be reimbursed with 80% of the costs associated with its share of the joint project - €420,000 ($0.56M approx.) over two years.
Others: * On September 3, 2013, VolitionRx, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, is lead partner of a consortium in a project valued at €779,493 (approx. US$1M) under the Eureka Eurostars scheme.
Therapeutic area: Cancer - Oncology
